Effectiveness of Terbinafine in Treating Toenail Onychomycosis and Associated Studies

In a study of 496 patients with toenail onychomycosis, terbinafine (TERB) at a dosage of 250 mg/day was significantly more effective than intermittent itraconazole (ITRA) in achieving various cures at weeks 48 and 72, especially in patients aged 50 years and older. TERB also showed a low incidence of mild to moderate adverse events. Another study reported hair depigmentation in a 69-year-old patient treated with a chemotherapeutic agent, suggesting it may affect c-kit signaling. A survey in São Paulo involving 36 patients with androgenetic alopecia highlighted the early onset of hair loss and its emotional impact, with different concerns for men and women. Additionally, a study of 504 patients with onychomycosis showed that debridement as an adjunct to terbinafine improved outcomes. Finally, a study of 168 patients found that both continuous and interval terbinafine regimens were effective against toenail onychomycosis, with topical bifonazole solution reducing recurrence rates. This study followed 119 patients for an average of 6.25 years.